Loading patent…
AssigneeCelera Corporation
InventorsDov SHIFFMAN, James J. DEVLIN, May LUKE, David ROSS
Estimating the term…
The present invention provides compositions and methods based on genetic polymorphisms that are associated with response to statin treatment, particularly for reducing the risk of cardiovascular disease, especially coronary heart disease (such as myocardial infarction) and stroke. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents and kits for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents and kits for their detection.
A method for determining whether a human's risk for cardiovascular disease (CVD) is reduced by treatment with an HMG-CoA reductase inhibitor, the method comprising testing nucleic acid from said human for the presence or absence of an allele at a polymorphism as represented by position 101 of any one of the nucleotide sequences of SEQ ID NOS:623-3661 or its complement, wherein the presence of said allele indicates said human's risk for CVD is reduced by treatment with said HMG-CoA reductase inhibitor.
2-3. (canceled)
9-12. (canceled)
(canceled)
(canceled)
A method for determining whether a human has an increased risk for cardiovascular disease (CVD), comprising testing nucleic acid from said human for the presence or absence of an allele at a polymorphism as represented by position 101 of any one of the nucleotide sequences of SEQ ID NOS:623-3661 or its complement, wherein the presence of said allele indicates said human has an increased risk for CVD.
A method for reducing risk of cardiovascular disease (CVD) in a human, comprising administering to said human an effective amount of an HMG-CoA reductase inhibitor, wherein said human has been identified as having an allele at a polymorphism as represented by position 101 of any one of the nucleotide sequences of SEQ ID NOS:623-3661 or its complement, and wherein the presence of said allele indicates said human's risk for CVD is reduced by treatment with said HMG-CoA reductase inhibitor.
33-34. (canceled)
37-38. (canceled)
Dependencies are inferred from the claim text.